AMBLER, PA—Allergy Technologies LLC, manufacturer of ActiveGuard Mattress Liners, is funding a second year of bed bug research at The Ohio State University with an additional grant of more than $100,000. This grant is an extension of last year’s support by the company that enabled the launch of this research initiative.
“Allergy Technologies’ funding of this research allows us to continue and complete some very valuable studies and trials relating to bed bug behavior, control strategies, resistance, repellency and more,” says Dr. Susan Jones, principal investigator on the project. As part of the second year of the grant, Jones and her team of urban entomologists will continue to examine behavioral and feeding characteristics of bed bugs, including their response to existing and novel products related to bed bug management.
“The core rationale of this research is to improve pest management practices and protocols relating to the proper control of bed bugs,” she adds. “Year Two funding gives us the opportunity to apply the results from the important laboratory studies we completed in the first year, and transition into field studies while continuing to expand our fundamental behavioral research.”
Gus Carey, managing director and CEO of Allergy Technologies, acknowledged the strong affiliation that his company has with Jones and the OSU team. “We have been continuously impressed with the knowledge and dedication of Susan Jones and her group of urban entomologists,” he says. “Dr. Jones’ strong understanding of bed bugs and their habits was one of the key reasons for working with Ohio State in the first place. Her work over the past year has greatly enhanced our understanding how bed bugs behave in the field and we look forward to continuing that research to help us find working solutions to eliminate these pests.”
“Bed bug infestations have dramatically increased over the course of the last decade, making this research so much more valuable to the pest control community,” notes Joseph Latino, COO of Allergy Technologies. “This grant directly underscores Allergy Technologies’ principal business paradigm of continuing our focus on supporting both the pest control industry and inner-city communities through our Philanprofit efforts.”